Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3
Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.
How this was made
The 30-second read
Why it matters
The downgrade suggests near‑term downside risk, but long‑term fundamentals may still be attractive.
Market read
UHS price target cut could trigger short‑term selling pressure, influencing healthcare service stocks.
What to watch
Potential upside from de‑novo facility maturation and synergies not yet reflected in the price.
Background
Guggenheim analysts revised UHS's valuation after the company's third‑quarter earnings and updated guidance.
Ticker impact
Guggenheim lowered its price target on Universal Health Services to $201, citing weak Q3 results and reduced 2026 EBITDA guidance.
likely pressure as the market prices in the guidance downgrade and lower target.
The new target reflects weaker earnings and guidance, which typically prompts sell‑offs.
Market effects
May weigh on the broader healthcare services sector as peers could face similar valuation pressure.
Limited to U.S. markets where UHS trades.
Low, as the news is company‑specific.
Counterpoint
If the Q3 beat and cash flow remain strong, the target cut could be an overreaction.
Key entities
- companyUniversal Health Services
U.S. healthcare services provider (ticker UHS).
- analyst_firmGuggenheim
Equity research firm that issued the price‑target cut.




